Foldvari Research Group

Welcome to the Foldvari Research Group   

Drug Delivery and Pharmaceutical Nanotechnology Laboratory
 

Foldvari Lab picture banner.

Dr. Marianna Foldvari is a Professor of Pharmaceutical Sciences and the Canada Research Chair in Bionanotechnology and Nanomedicine (2007-2014) at the University of Waterloo’s School of Pharmacy. Dr. Foldvari’s expertise is in pharmaceutics, dosage forms, drug delivery system design (dermal, transdermal, transmucosal, ocular, and intranasal), nanotechnology, non-viral delivery methods and vaccine development.

Currently, the Foldvari Group is investigating novel materials, methods, mechanisms and pathways to enable the discovery and invention of needle-free administration of medicines. We are working on developing non-invasive drug delivery technologies and pharmaceutical products based on these technologies.

Our objectives are to:

  • Develop novel delivery systems and formulations for drugs, proteins, nucleic acids and vaccines
  • Create hybrid systems, e.g., DNA-nanoparticles, carbon nanotube composites and other unique structures
  • Create nanoprobe systems for diagnostics and repair of biological functions
  • Investigate natural and synthetic materials for fabrication of delivery and diagnostic systems
  • Create interfacing methods between physical and biological systems
  • Investigate molecular functions at the bio/nano interface using computer modelling and visualization of the delivery systems

Read More...

News

Monday, January 6, 2014

Congratulations Chilbert!

Congratulations to Chilbert Dong for successfully defending his Masters thesis titled "Characterization of Gemini Nanoparticle Assembly by Fluorescence Correlation Spectroscopy".

Friday, January 18, 2013

Congratulations Samih!

Congratulations to Samih Alqawlaq for successfully defending his Masters thesis titled “Non-viral gemini surfactant-phospholipid nanoparticles for topical gene delivery to the retina.”

Saturday, September 1, 2012

Welcome Roger!

Ding Wen (Roger) Chen received his BSc from the Biomedical Science program at the University of Waterloo and has joined the Foldvari group as a Master student working on applying gene therapy to impede the progression of glaucoma.